# Zoledronic Acid for the Prevention of TDF-sparing ART-induced Bone Mass Density Loss in Treatment-naive HIV Positive Individuals

> **NCT06762730** · PHASE4 · RECRUITING · sponsor: **Hadassah Medical Organization** · enrollment: 110 (estimated)

## Conditions studied

- HIV Infected Individuals
- Osteopenia

## Interventions

- **DRUG:** Zoledronic Acid 5 mg/Bag 100 ml Inj

## Key facts

- **NCT ID:** NCT06762730
- **Lead sponsor:** Hadassah Medical Organization
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-09
- **Primary completion:** 2028-12-01
- **Final completion:** 2032-12-01
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2025-09-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06762730

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06762730, "Zoledronic Acid for the Prevention of TDF-sparing ART-induced Bone Mass Density Loss in Treatment-naive HIV Positive Individuals". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06762730. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*